Who We Are

Syreon is a dynamic clinical research corporation specializing in the use of electronic systems for international health research. Syreon combines advanced computing technologies, specialized therapeutic expertise and global reach to provide leading edge clinical research programs ideally adapted to the fast pace of modern drug evaluation.

ClinStream™

Our powerful Syreon ClinStream™ electronic clinical research system links research partners in over 40 countries with speed, security and accuracy, and enables the seamless integration of clinical, laboratory, health outcomes and economic data for comprehensive clinical evaluation of treatment effectiveness and value.

Clients

Syreon partners with an elite portfolio of global pharmaceutical corporations, emerging biotechnology companies and academic networks to identify therapeutic trends, streamline new drug investigation, monitor clinical use and economic value, and control development costs by accelerating time to market in today's competitive environment.

News and Updates ||
June 01, 2011: Syreon initiates a multicentre international phase IV study including over 3,000 subjects in Europe to track the use of prophylactic and therapeutic medications in osteoporosis, and the outcomes, consequences and health and economic impact and of treatment. The study will be conducted using ClinStream electronic study software with real-time data analysis and study reporting.
June 01, 2011: Syreon initiates a global phase IV study investigating reproductive technologies and health outcomes. The study will be conducted using ClinStream electronic study software with real-time data analysis and study reporting.
March 01, 2011: Syreon has launched an update of its highly recognized and fully validated ClinStream e-clinical research management application developed specifically for multi-national "direct-to-patient" clinical studies. This new flexible format, adapted for both MS and Mac operating systems with multi-language capability, is designed to enable direct patient response within formal clinical studies. ClinStream is now capable of linking a virtually unlimited number of patients and study sites simultaneously to accelerate global interventional, observational and economics research with rigor and precision, offering reduced cycle time and enhanced value.
February 01, 2011: Syreon launches a multicentre international phase IV study including over 1,000 subjects in North America and Europe to track the symptoms and severity of migraine, the use of prophylactic and therapeutic medications, and the outcomes and consequences of treatment. The study will be conducted using ClinStream electronic study software with real-time data analysis and study reporting.
February 01, 2011: Syreon launches a multicentre, multi-country international phase IV study to track the population epidemiology, presentation and management of sexually communicated viral disease in the Middle East and Eastern Europe. The study will be conducted using ClinStream electronic study software with real-time data analysis and study reporting.
January 01, 2011: Syreon is in the process of a 5-year clinical support program for the clinical management and research analysis of biologics therapy in chronic disease involving over 30,000 subjects. This study, one of the largest of its kind in the world, is conducted electronically using a select version of the recognized ClinStream e-clinical research management application with specialized data entry for clinical care, automated data loading for simplified
January 01, 2010: Syreon launches a multicentre international European phase IV study in arthritis to track the use of non-steroidal anti-inflammatory drugs and the incidence of treatment failure. The study will be conducted using ClinStream™ electronic study software with real-time data analysis and study reporting.
December 15, 2009: Syreon successfully completed a major electronic clinical study in diabetes in 5 countries in Asia and the Middle East using its ClinStream™ e-clinical research program modular application. Study trial set-up was expedited in 8 weeks, and almost 1,400 subjects were recruited in less than 4 weeks. Data cleaning and export were completed within 7 days of the last patient visit, consistent with the accelerated performance guaranteed by Syreon digital research services.
July 01, 2009: Syreon has launched a new streamlined version of its highly recognized and fully validated ClinStream™ e-clinical research management application developed specifically for observational late-phase clinical studies. This new flexible format is capable of linking a virtually unlimited number of study sites to accelerate global observational and economics research with rigor and precision, in a reduced cycle time and with enhanced value.
January 01, 2009: Syreon Research Institute (SRI) is established in Budapest, Hungary to provide international expertise in health economics. SRI operations are guided by Dr. Kalo, CEO and Dr. Voko, Medical Director, who bring extensive expertise in cutting edge health economics and health policy from both academic and corporate sectors. SRI is engaged in providing a broad range of economics training, consulting, research and analysis to global pharmaceutical and biotechnology companies across Europe and the United States.
June 01, 2008: Syreon is conducting a 5-year clinical support program for the clinical management and research analysis of biologics therapy in chronic disease involving over 25,000 subjects. This study, one of the largest of its kind in the world, is conducted electronically using a select version of the recognized ClinStream™ e-clinical research management application with automated data loading and on-line analytical processing to enable the accelerated cycle time required for clinical interpretation and management.
June 07, 2007: Syreon's biometricians provide essential statistical results supporting effectiveness of a new, first-in-class agent designed to reduce the rate of loss of kidney function in patients with an orphan indication. The results of the pivotal phase II/III study have been published in the New England Journal of Medicine (N Engl J Med 2007;356:2349-60).